Renishaw, a global engineering company with expertise in healthcare, is exhibiting at the International Symposium on Paediatric Neuro-Oncology (ISPNO) 2018. From June 30th to July 3rd at the Hyatt Regency Hotel in Denver, Colorado, USA the company will showcase its neurological products which improve accuracy and reduce procedure time in neurosurgery.

The 2018 meeting marks the 18th year of ISPNO, which has become the leading event for advancing clinical and translational research with technical advances for infants, children and adolescents with central nervous system tumours. The symposium includes an education day for junior staff and trainees, a neurosurgical programme and a programme for neuro-oncology nurses.

At the symposium, Renishaw will highlight the benefits of the neuromate ® a stereotactic robot for a broad range of neurosurgical procedures, including biopsies. The neuromate robot can be used to establish a histological diagnosis with minimal risks, without the use of a stereotactic frame. This expands the possible trajectories into the brain to improve access to lesions in the brain.

Visitors will also be introduced to the neuroinfuse™ drug delivery system, a device currently only available for use in approved clinical trials. The investigational device allows intraparenchymal drug delivery, which bypasses the blood brain barrier and shows promise in providing a step change in treating neurological conditions. Renishaw is seeking academic, clinical and industrial partners interested in treating neuro-oncology and neurodegenerative diseases.

'Communicating technological advancements to the international neuro-oncology community is essential in enhancing patient care,' explained Stuart Campbell, Clinical Sales Development Manager at Renishaw. 'ISPNO provides a forum for open discussion and knowledge sharing or the latest research and developments, which ultimately will allow the industry to progress and impact children's lives.'

Renishaw is developing a range of engineering solutions for the diagnosis and treatment of neurological diseases. For more information visit www.renishaw.com/neuro

Attachments

  • Original document
  • Permalink

Disclaimer

Renishaw plc published this content on 13 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 13 June 2018 15:42:02 UTC